BUTOCONAZOLE NITRATE

BUTOCONAZOLE NITRATE
(byoo-toe-koe'na-zole)
Femstat 3, Gynazole 1
Classifications: azole antifungal antibiotic;
Therapeutic: antifungal
; antibiotic
Prototype: Fluconazole
Pregnancy Category: C

Availability

2% cream

Action

Imidazole derivative with antifungal activity. Alters fungal cell membrane permeability, permitting loss of phosphorous compounds, potassium, and other essential intracellular constituents with consequent loss of ability to replicate. Action takes place primarily on medicated infected surface tissues.

Therapeutic Effect

Has fungicidal effect as well as effectiveness against some gram-positive bacteria.

Uses

Local treatment of vulvovaginal candidiasis.

Contraindications

Pregnancy (category C). Safety in children <12 y is not established.

Cautious Use

Hypersensitivity to azole antifungals; HIV patients; diabetes mellitus; lactation.

Route & Dosage

Vulvovaginal Candidiasis
Adult: Topical 1 applicator full intravaginally h.s. for 3 d, may be extended another 3 d if needed
Pregnant women: Topical 1 applicator full intravaginally h.s. for 6 d

Administration

Topical Intravaginal
  • Continue treatment even during menstruation.
  • Store medication at 15°–30° C (59°–86° F); avoid extreme temperature and freezing.

Adverse Effects (≥1%)

Urogenital: Vulvar or vaginal burning, vulvar itching, discharge, soreness, swelling; urinary frequency and burning. Skin: Itching of fingers. CNS: Headache.

Pharmacokinetics

Absorption: Small amount absorbed systemically from intravaginal administration. Distribution: Crosses placenta in animals. Metabolism: In liver. Elimination: In both urine and feces within 4–7 d. Half-Life: 21–24 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor for therapeutic effectiveness. Candidiasis in nonpregnant women is usually controlled in 3 d.

Patient & Family Education

  • Take medication exactly as prescribed; do not increase or decrease dosage or discontinue or extend treatment period. Contact physician if symptoms (vaginal burning, discharge, or itching) persist; drug may be discontinued if acute irritation occurs.
  • Patient's sexual partner should wear a condom during intercourse.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(31)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 05/21/2025 (0.01)
×
Wait 20 seconds...!!!